Publications & Media

Federal Circuit Court Decisions For Week Ending August 2, 2019

Amgen Inc. v Coherus Biosciences Inc., No. 2018-1993 (July 29, 2019) (precedential) (3-0); Patent No. 8,273,707

Key points:

  • If multiple arguments are made during prosecution, estoppel can attach to each argument individually. However, distinguishing the prior art based on a combination of arguments does not necessarily attach estoppel to each argument individually.
  • Estoppel may attach even if the argument does not secure allowance of the application.


Solutran, Inc. v. Elavon, Inc., Nos. 2019-1345, 2019-1460 (July 30, 2019) (precedential) (3-0); Patent No. 8,311,945

Key point:

  • Merely reciting conventional steps to process checks in order to shorten the time before funds are available to a merchant, without an inventive step, does not satisfy §101 even if the checks are both physically and electronically processed.


In re Corel Software, No. 2019-124 (August 1, 2019) (non-precedential); Patent Nos. 6,731,309, 7,827,483, 8,700,966

Key point:

  • Asserting new claims after a first stay has been lifted upon completion of post-grant review of the asserted patents can result in a second stay and subsequent post-grant review.

Hylete LLC v. Hybrid Athletics, LLC, No. 2017-2057_ (August 1, 2019) (precedential) (3-0); U.S. Serial No. 85,837,045

Key point:

  • In trademark opposition proceedings, arguments regarding the common law rights of a trademark can be waived on appeal if not presented before the Board.

Celgene Corp. v. Peter, Nos. 2018-1167, 2018-1168, 2018-1169, 2018-1171 (July 30, 2019) (precedential) (3-0); Patent Nos. 6,045,501, 6,315,720

Key point:

  • Subjecting a pre-AIA patent to an IPR is not an unconstitutional taking under the Fifth Amendment.

Virnetx Inc. v. Apple, Inc., Nos. 2017-1591, 2017-1592, 2017-1593 (August 1, 2019) (precedential) (2-1); Patent Nos. 7,418,504, 7,921,211

Key point:

  • An invalidity decision is final under §317(b) once the deadline to file a certiorari petition on invalidity has lapsed. A final decision under §317(b) does not require a complete exhaustion of all appealable issues.